Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy

Executive Summary

The move to deny coverage for an approved orphan drug is ‘highly unusual,' NORD VP says. 'We certainly hope this isn’t going to set a precedent.'

Advertisement

Related Content

Antibacterial Development: Industry Cautious About Role Of Animal Models
Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage
Patient-Centered Promotion? Marathon's Non-Launch Of Emflaza Illustrates Challenge Of New Era
Marathon's High-Priced Window May Not Stay Open Long
Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch
Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?
J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More
Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales
Sarepta's Eteplirsen Approved After Contentious Internal Debate
CMS Wants To Facilitate Value-Based Discounts For HCV Drugs In Medicaid

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel